Zobrazeno 1 - 10
of 88
pro vyhledávání: ''
Autor:
Shinjiro Sakamoto, Shintaro Miyamoto, Takeshi Masuda, Satoshi Nakao, Toshihito Otani, Noboru Hattori, Taku Nakashima, Hironobu Hamada, Hiroshi Iwamoto, Yasushi Horimasu, Kazunori Fujitaka, Kakuhiro Yamaguchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:857-865
Cytotoxic chemotherapy-induced lung injury is a fatal complication in patients with lung cancer and interstitial lung disease (ILD). We aimed to evaluate the association between hyperglycemia and this form of lung injury in patients with lung cancer
Autor:
Yusuke Tanigawara, Takahisa Kawamura, Akira Ono, Kazuhisa Nakashima, Tateaki Naito, Chiyo K. Imamura, Toshiaki Takahashi, Tetsuhiko Taira, Haruyasu Murakami, Kazushige Wakuda, Shota Omori, Taisei Mushiroda, Hirotsugu Kenmotsu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:605-614
Severe hepatotoxicity induced by the standard dose of gefitinib (250 mg daily) often becomes manageable by dose reduction to 250 mg every other day. Thus, we hypothesized that systemic exposure of standard-dose gefitinib in patients with experience o
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The immune checkpoint inhibitor nivolumab is commonly used for non-small-cell lung cancer treatment. Immune checkpoint inhibitors cause immune-related adverse events, including interstitial pneumonia. However, there are no studies on the risk
Autor:
Yasuhiro Kato, Kageaki Watanabe, Shoko Kawai, Makiko Yomota, Yukio Hosomi, Tatsuru Okamura, Yusuke Okuma
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background Few studies have investigated the clinical efficacy of third- and later-line of chemotherapy after standard chemotherapy for previously treated advanced non-small cell lung cancer (NSCLC). We prospectively evaluated the efficacy and safety
Autor:
Martin Johnson, Haiyi Jiang, Mitsuo Higashimori, Fredrik Nyberg, Weifeng Tang, Helen Tomkinson, Yohji Itoh, Yusuke Tanigawara, Toshio Kawata
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:849-858
A prospective, multicenter, large-scale cohort with a nested case–control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received
Autor:
Diane Damotte, Marie Wislez, Philippe Icard, Marco Alifano, Claude Guinet, Jérôme Alexandre, Frédéric Batteux, Jennifer Arrondeau, Mathilde Prieto, Rémi Hervochon, Ludovic Fournel, Pascaline Boudou-Rouquette, François Goldwasser
Publikováno v:
Cancer chemotherapy and pharmacology. 86(4)
The widespread use of Nivolumab results in an increasing number of side effects and adverse events. Herein, we evaluated the impact of Nivolumab on crude and normalized pulmonary artery diameter (PAD).We analyzed clinical, morphometric, pathological
Autor:
Ichiro Kinoshita, Masaharu Nishimura, Jun Sakakibara-Konishi, K. Ito, Noriaki Sukoh, Masao Harada, Satoshi Fuke, Kosuke Nakano, Shinichi Fukumoto, Hiroshi Isobe, Satoshi Oizumi, Yutaka Nishigaki, Toraji Amano, Hirotoshi Dosaka-Akita, Toshiyuki Harada, Kenji Akie, Kei Takamura, Yuka Fujita
Publikováno v:
Cancer chemotherapy and pharmacology. 86(1)
This study evaluated the efficacy and safety of platinum plus gemcitabine (P/G) combinations as postoperative adjuvant chemotherapies for non-small cell lung cancer. Patients with postoperative stage IB–IIIA non-small cell lung cancer were randomly
Autor:
Ryosuke Chiba, Junya Sato, Satoshi Moriguchi, Kohei Yamauchi, Kenzo Kudo, Naoto Morikawa, Heisuke Saito, Satoru Nihei
Publikováno v:
Cancer Chemotherapy and Pharmacology. 80:545-553
Afatinib maleate (AFA) is a second-generation, tyrosine kinase inhibitor (TKI) treatment for specific variants of non-small cell lung cancer exhibiting epidermal growth factor receptor (EGFR) mutations. In this study, we measured the blood AFA levels
Autor:
Hideki Ohta, Kimio Yasuda, Takahiro Hayashi, Teppei Yamaguchi, Minori Funatsu, Sumie Murai, Kaori Ito, Yoshiaki Ikeda, Moeko Ujita, Kazuyoshi Imaizumi, Kenji Kawada, Shigeki Yamada, Yosuke Ando
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Pemetrexed (PEM) is an anticancer agent used for the treatment of non-small cell lung cancer, malignant pleural mesothelioma and thymoma. Reportedly, PEM has higher efficacy and safety when used in combination with platinum-based agents. Howe
Autor:
Koshi Yokomura, Kazunari Yamada, Yuichi Ozawa, Hirotsugu Hasegawa, Masayuki Tanahashi, Hiroshi Niwa, Takashi Matsui, Daisuke Akahori, Keigo Koda, Takafumi Suda, Takefumi Abe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:1031-1038
Pre-existing interstitial lung disease (pre-ILD) increases the risk of chemotherapy-related lung injury (CRLI). However, whether the risk varies by type of anti-cancer cytotoxic agent in patients with pre-ILD is unknown. In this study, we hypothesize